CD274 and non-small cell lung carcinoma: This open-label phase-III study revealed that the efficacy of nivolumab for the treatment of PD-L1 positive stage IV non-small cell lung cancer (NSCLC) patients in a first-line setting was similar with platinum-based chemotherapy (Carbone et al., 2017).